On October 21, 2022, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and InxMed (Nanjing) Co., Ltd. ("InxMed") jointly announced that their co-developed antibody drug INES103 has been formally accepted by the Center for Drug Evaluation (CDE) for IND application, with the acceptance number CXSL-2200537.

On September 21, 2022, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") successfully held the "Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ESG401 in Patients with Locally Advanced/Metastatic Solid Tumors (ESG401-101)" clinical investigator meeting online. Prominent clinical experts and their teams from 20 top-tier oncology clinical research institutions across the country participated in the meeting. The launch of the Phase Ib/II study was announced at the meeting.